New FDA-approved therapy provides better quality of life for patients with midgut neuroendocrine tumors

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.

More From BioPortfolio on "New FDA-approved therapy provides better quality of life for patients with midgut neuroendocrine tumors"